Galapagos and BASF Extend Research Collaborations
News Feb 02, 2006
These extensions will further progress discovery research services for BASF programmes undertaken by Galapagos' service division BioFocus in 2005.
Across the various programmes, BioFocus will offer biology, synthetic and computational chemistry services, plus access to its biologically-targeted SoftFocus® Kinase and GPCR compound libraries against further BASF targets.
Under the terms of the extension agreements, BASF will pay compound supply and access fees and will fund research activities. Total contract value of the extensions announced today will exceed € 700,000.
"We are delighted that BASF has chosen to extend these collaborations with BioFocus," said Onno van de Stolpe, CEO of Galapagos.
"We believe that our expertise in the area of kinase and GPCR biology and chemistry, together with our proprietary compound libraries, place BioFocus in an excellent position to progress BASF's discovery programmes rapidly."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE